Therapy
Tocilizumab
Monoclonal antibody targeting IL-6R.
Also called: tocilizumab, Actemra, TCZ, RoActemra
In short
- 1What it is: a therapy in therapies and applications.
- 2How it connects: acts on 4 and is affected by 0 concepts — mostly 1 receptor, 2 disease, 1 biomarker.
- 3Where it sits: therapy, trial on the 15-step immune chain.
What it does
Humanised anti-IL-6Rα (soluble+membrane); IV+SC; Clinical warning: suppresses CRP production (IL-6R blocked → hepatic CRP synthesis reduced) → fever and CRP cannot monitor for infection in patients on tocilizumab, patient education mandatory; lipid monitoring 4-8 weeks; first-line CRS Grade 2+ (8mg/kg IV); GCA first biologic approval; RA, sJIA, COVID-19 ARDS
Its connections at a glance
Each dot is a concept directly linked to Tocilizumab. Colours show the kind of concept.
Sources & evidenceloading…
Loading reviewed sources…
Graph ID I003 · concept status: established. Select any connection above to inspect evidence for that specific link.